Clifton Life Sciences (CLS) is a leader in the emerging field of molecular diagnostics for both blood and tissue based pathology, developing cell- and tissue-based diagnostic tests for personalized oncological medicine. The company’s products and services are based on its proprietary technology involving the identification of molecular signatures for a variety of neoplastic processes. CLS is developing a novel blood detection system for point-of-care diagnostic applications including neuroendocrine tumors and other cancers. The CLS platform incorporates a molecular gene cluster signature configuration which produces high performance quantitative laboratory blood test results with the facility of rapid qualitative diagnostic assays.


Product Aims

The scientific strategy of CLS is the development of a series of gene signatures that identify the disease.          Learn More


The Surveillance Epidemiology and End Results (SEER) database (1973-2006), contains 48,195 NENs.                         Learn More

PCR Tests

The PCR-based blood test exhibited correct call rates of 91-97% with sensitivities and specificities.                               Learn More


Treatment responses to radiation-based therapies, detection of residual disease and accurate quantitation of the proliferome.Learn More